公司融资与商业扩张 - 公司完成超额认购的2亿美元融资以加速其在美国和欧洲的商业推广 [1] - 计划到2026年第二季度末在美国建立约40名销售专业人员团队在欧洲建立20-30名团队打造全球最大的Agentic Commerce专属销售团队之一 [3] - 扩大的销售和营销投资将专注于加速其Brain Commerce平台的部署包括对话式商务视觉搜索和智能结账 [4] 核心技术与市场定位 - 公司是Agentic Commerce革命的先驱致力于引领万亿美元级别的人们与品牌交易方式的转型 [1][4] - Brain Commerce平台是公司Agentic和Conversational Commerce的核心引擎 [2][4] - Agentic Commerce技术旨在提供可衡量的投资回报率更高的参与度转化率和收入通过AI驱动的个性化和自主购买旅程重新定义零售商与客户的互动方式 [4] 管理层任命与战略执行 - 任命前微软高管Elizabeth Lachhar为美国销售高级副总裁其曾管理数十亿美元销售额的损益表 [2][8] - Lachhar将于2026年1月开始负责领导全国性的上市组织推动企业采用Brain Commerce平台 [2][9] - 此次任命旨在凭借其领导力和深厚的企业经验将多年的创新转化为市场主导地位 [4]

Rich Deakin joins QLE Ltd as Senior Vice President and Managing Director UK Strategic Projects, bringing significant nuclear industry experienceWASHINGTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced a regulatory progress update in its initiative to produce High-Assay Low Enriched Uranium (“HALEU”) in ...

Company to hold a conference call at 8:00 a.m. ETDURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. P ...

A collaboration that turns everyday travel into a moment of luxurious self-careNEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- XWELL (Nasdaq: XWEL) (“XWELL” or the “Company”), a leader in wellness solutions for people on the go, today announced they are teaming up with Ostrichpillow – the masters of mindful rest – to launch a co-branded, limited-edition Eye Mask in XWELL's Blue Breeze colorway. Built for function and a touch of everyday luxury, this exclusive collab celebrates both brands' shared mission to mak ...

Empowering travel professionals and paving the way for broader integrationNEW YORK, NY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI, GFAIW), an AI-driven technology company providing smart solutions in automation, robotics, Agentic AI and secured logistics, today announced the launch of DVGO Beta 2.0, marking a major milestone in its AI-first product roadmap and the start of its marketing expansion. DVGO, Guardforce AI’s first travel plannin ...

Conference call today at 9:00 am ETQ3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue growth with FUROSCIX®Program updates: sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target ahead of schedule MNKD-201 IPF ...

SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The first patient in the cohort (the fourth patient in the trial) received an initial dose of CER-1236 at twice the initial dose of t ...

-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has concluded patient enrollment in Part A of its Phase 2 ASCEND study evaluating PCRX-201 (enekinragene ...

Quanzhou, China, Nov. 05, 2025 (GLOBE NEWSWIRE) -- INLIF LIMITED (Nasdaq: INLF) (the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced the official commencement of Phase II construction of its digital intelligent manufacturing base project (the “Project”) in Nan’an city, Fujian Province. The groundbreaking ceremony was attended by Mr. Wang Lianzan, Mayor of Nan’an City, underscoring the sig ...

– Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency – – BROOKLYN and BROADWAY pooled MACE analysis published in the Journal of the American College of Cardiology, while the BROADWAY pre-specified Alzheimer’s substudy was published in the Journal of Prevention of Alzheimer's Disease – – $756.0 million in cash, cash equivalents and marketable securities at September 30, 2025 – NAARDEN, the Netherlands and MIAMI, Nov. 05 ...